HSI Ends at 26,085, Gaining 149 Points; HSTI Finishes at 5,662, Up 47 Points; PING AN Surges Over 6%; HANSOH PHARMA, ENN ENERGY, SINOTRUK Reach Record Highs; Market Turnover Increases
Written by Emily J. Thompson, Senior Investment Analyst
Source: aastocks
Updated: 1 hour ago0mins
Market Performance: The Hang Seng Index (HSI) rose by 149 points (0.6%) to close at 26,085, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also saw gains, closing at 5,662 and 9,198 respectively, with a total market turnover of $210.47 billion.
Active Heavyweights: Notable stock movements included PING AN (+6.7%), XIAOMI (+1.9%), and MEITUAN (+1%), while TENCENT experienced a slight decline of 0.3%.
HSI & HSCEI Constituents: Key performers included CHINA LIFE (+5.5%), BIDU-SW (+5%), and HANSOH PHARMA (+3.7%), while SHENZHOU INTL saw a significant drop of 3.4%.
HSMI & HSSI Constituents: HAICHANG HLDG faced a sharp decline of 17.5%, and RIMAG GROUP dropped by 13.7%, whereas SINOTRUK gained 3.5%, reaching a new high.
00388.HK
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on 00388
Wall Street analysts forecast 00388 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00388 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 406.400
Low
Averages
High
Current: 406.400
Low
Averages
High
HSBC
HSBC Global Research
maintain
$530
2025-11-13
Reason
HSBC
HSBC Global Research
Price Target
$530
2025-11-13
maintain
Reason
The analyst rating from HSBC Global Research for HKEX is based on the belief that the acquisition of a 20% stake in CMU OmniClear Holdings for $455 million is a positive move for the company. They noted that while the transaction will have a limited short-term financial impact, the commercialization of CMU OmniClear could provide upside potential. Additionally, HKEX's history of driving market development through financial infrastructure enhancements suggests a promising growth potential for its financial innovation center business. As a result, HSBC maintained a "Buy" rating with a target price of $530.
DBS Research
DBS Research
Buy
maintain
$540
2025-11-07
Reason
DBS Research
DBS Research
Price Target
$540
2025-11-07
maintain
Buy
Reason
DBS Research has issued a Buy rating on HKEX due to several positive factors: strong momentum in the Hong Kong bourse, improved liquidity and investment sentiment, attractive valuations of Hong Kong tech stocks compared to other markets, and supportive government policies and stimulus measures. They have also raised their average daily turnover forecast for HKEX, indicating confidence in the market's performance. The target price remains at HKD540.
UOB Kay Hian
UOB Kay Hian
Buy
maintain
$548
2025-11-07
Reason
UOB Kay Hian
UOB Kay Hian
Price Target
$548
2025-11-07
maintain
Buy
Reason
The analyst rating from UOB Kay Hian for HKEX is a "Buy" due to a significant 56% year-over-year increase in net profit for 3Q25, which exceeded the broker's expectations by 7%. This strong performance was attributed to robust growth in core revenue, a record-breaking average daily trading volume, and strong IPO momentum. Despite a decline in net interest income, the overall positive financial results led to the decision to maintain a Buy rating and raise the target price to HKD548.
CICC
CICC
Outperform
maintain
$500
2025-11-07
Reason
CICC
CICC
Price Target
$500
2025-11-07
maintain
Outperform
Reason
The analyst rating from CICC for HKEX (00388.HK) is maintained at "Outperform" with a target price of $500 due to the company's strong financial performance in the third quarter of 2025. The total revenue grew by 45% year-over-year to $7.775 billion, and profit increased by 56% year-over-year to $4.9 billion, which exceeded market expectations. This growth was attributed to the rapid expansion of market-related businesses driven by active trading and solid investment income. CICC's forecasts for 2025-2026 earnings remain largely unchanged, supporting their positive outlook and indicating an 18% upside potential based on the target price.
See All Ratings
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?